Payment overview · 2025
General Payments
$301.39
13 reported records · 9 companies
Healthcare provider profile · identity verified
Jill Anne Saranthus, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JASPER, GA · NPI 1346352721
Verified facts
What the public records show
CMS Open Payments records show Jill Anne Saranthus, FNP received $301.39 in general payments during 2025 across 13 reported records.
Corcept Therapeutics accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $62.74 | 20.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.35 | 18.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.40 | 15.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.99 | 14.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.63 | 7.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $19.02 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.69 | 6.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.18 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.39 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $301.39 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $62.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.40 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 242 | 78 |
| Lisinopril | Lisinopril | 205 | 69 |
| Alprazolam | Alprazolam | 192 | 36 |
| Trazodone Hcl | Trazodone Hcl | 174 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 170 | 61 |
| Gabapentin | Gabapentin | 170 | 51 |
| Losartan Potassium | Losartan Potassium | 166 | 47 |
| Omeprazole | Omeprazole | 165 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 55 |
| Prednisone | Prednisone | 132 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 43 |
| Montelukast Sodium | Montelukast Sodium | 115 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 29 |
| Sertraline Hcl | Sertraline Hcl | 104 | 32 |
| Celecoxib | Celecoxib | 98 | 30 |
| Metformin Hcl Er | Metformin Hcl | 98 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 17 |
| Famotidine | Famotidine | 97 | 27 |
| Temazepam | Temazepam | 91 | 17 |
| Metformin Hcl | Metformin Hcl | 87 | 24 |
| Meloxicam | Meloxicam | 81 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 21 |
| Furosemide | Furosemide | 78 | 26 |
| Simvastatin | Simvastatin | 74 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 22 |
| Ozempic | Semaglutide | 69 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 59 |
| Spironolactone | Spironolactone | 67 | 31 |
| Carvedilol | Carvedilol | 63 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 23 |
| Amoxicillin | Amoxicillin | 60 | 50 |
| Lovastatin | Lovastatin | 60 | 19 |
| Jardiance | Empagliflozin | 59 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 15 |
| Aripiprazole | Aripiprazole | 55 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Allopurinol | Allopurinol | 53 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 18 |
| Azithromycin | Azithromycin | 50 | 48 |
| Potassium Chloride | Potassium Chloride | 49 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 46 | 12 |
| Estradiol | Estradiol | 45 | 15 |
| Glipizide | Glipizide | 45 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 34 |
| Azelastine Hcl | Azelastine Hcl | 39 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 12 |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 21 |
| Fluconazole | Fluconazole | 36 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | 12 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 18 |
| Atenolol | Atenolol | 34 | 11 |
| Ibuprofen | Ibuprofen | 34 | 18 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Nystatin | Nystatin | 33 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 13 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 12 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Naproxen | Naproxen | 25 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 14 |
| Methylprednisolone | Methylprednisolone | 17 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Androgel | Testosterone | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $301.39 · 13 records | Corcept Therapeutics | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Heplisav-B, JARDIANCE, Korlym, Ozempic, QULIPTA, UBRELVY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error